My ePortfolio Register   

Ramucirumab for gastric cancer does not get UK approval

NICE does not recommend ramucirumab (also known as Cyramza and manufactured by Eli Lilly and Company) for people whose stomach cancer has spread or if they have cancer that develops at the point where the food pipe joins to the stomach.

The independent appraisal committee concluded that ramucirumab does not provide enough benefit to patients to justify its high cost and did not qualify for end of life considerations, so it was not recommended.

Source: NICE



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence